Paying users zone. Data is hidden behind: .
Get 1-month access to Eli Lilly & Co. for $19.99, or
get full access to the entire website for at least 3 months from $49.99.
We accept:
This is a one-time payment. There is no automatic renewal.
Common Stock Valuation Ratios (Price Multiples)
Quarterly Data
Valuation ratios measure the quantity of an asset or flaw (e.g., earnings) associated with ownership of a specified claim (e.g., a share of ownership of the enterprise).
Historical Valuation Ratios (Summary)
Eli Lilly & Co., historical price multiples (quarterly data)
Based on: 10-K (filing date: 2021-02-17), 10-Q (filing date: 2020-10-28), 10-Q (filing date: 2020-07-31), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-19), 10-Q (filing date: 2019-10-25), 10-Q (filing date: 2019-08-02), 10-Q (filing date: 2019-05-02), 10-K (filing date: 2019-02-19), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-07-25), 10-Q (filing date: 2018-04-27), 10-K (filing date: 2018-02-20), 10-Q (filing date: 2017-10-27), 10-Q (filing date: 2017-07-28), 10-Q (filing date: 2017-05-01), 10-K (filing date: 2017-02-21), 10-Q (filing date: 2016-10-28), 10-Q (filing date: 2016-07-28), 10-Q (filing date: 2016-04-29).
Valuation ratio | Description | The company |
---|---|---|
P/E ratio | The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. | Eli Lilly & Co.’s P/E ratio decreased from Q2 2020 to Q3 2020 but then increased from Q3 2020 to Q4 2020 exceeding Q2 2020 level. |
P/OP ratio | Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. | Eli Lilly & Co.’s P/OP ratio decreased from Q2 2020 to Q3 2020 but then increased from Q3 2020 to Q4 2020 exceeding Q2 2020 level. |
P/S ratio | An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. | Eli Lilly & Co.’s P/S ratio decreased from Q2 2020 to Q3 2020 but then increased from Q3 2020 to Q4 2020 exceeding Q2 2020 level. |
P/BV ratio | The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company’s required rate of return and its actual rate of return. | Eli Lilly & Co.’s P/BV ratio decreased from Q2 2020 to Q3 2020 but then increased from Q3 2020 to Q4 2020 not reaching Q2 2020 level. |
Price to Earnings (P/E)
Eli Lilly & Co., historical P/E calculation (quarterly data)
Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No. shares of common stock outstanding1 | ||||||||||||||||||||||||||
Selected Financial Data (US$) | ||||||||||||||||||||||||||
Net income (loss) (in thousands) | ||||||||||||||||||||||||||
Earnings per share (EPS)2 | ||||||||||||||||||||||||||
Share price1, 3 | ||||||||||||||||||||||||||
Valuation Ratio | ||||||||||||||||||||||||||
P/E ratio4 | ||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||
P/E Ratio, Competitors5 | ||||||||||||||||||||||||||
Abbott Laboratories | ||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||
Illumina Inc. | ||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||||
Zoetis Inc. |
Based on: 10-K (filing date: 2021-02-17), 10-Q (filing date: 2020-10-28), 10-Q (filing date: 2020-07-31), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-19), 10-Q (filing date: 2019-10-25), 10-Q (filing date: 2019-08-02), 10-Q (filing date: 2019-05-02), 10-K (filing date: 2019-02-19), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-07-25), 10-Q (filing date: 2018-04-27), 10-K (filing date: 2018-02-20), 10-Q (filing date: 2017-10-27), 10-Q (filing date: 2017-07-28), 10-Q (filing date: 2017-05-01), 10-K (filing date: 2017-02-21), 10-Q (filing date: 2016-10-28), 10-Q (filing date: 2016-07-28), 10-Q (filing date: 2016-04-29).
1 Data adjusted for splits and stock dividends.
2 Q4 2020 Calculation
EPS
= (Net income (loss)Q4 2020
+ Net income (loss)Q3 2020
+ Net income (loss)Q2 2020
+ Net income (loss)Q1 2020)
÷ No. shares of common stock outstanding
= ( + + + )
÷ =
3 Closing price as at the filing date of Eli Lilly & Co.’s Quarterly or Annual Report.
4 Q4 2020 Calculation
P/E ratio = Share price ÷ EPS
= ÷ =
5 Click competitor name to see calculations.
Valuation ratio | Description | The company |
---|---|---|
P/E ratio | The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. | Eli Lilly & Co.’s P/E ratio decreased from Q2 2020 to Q3 2020 but then increased from Q3 2020 to Q4 2020 exceeding Q2 2020 level. |
Price to Operating Profit (P/OP)
Eli Lilly & Co., historical P/OP calculation (quarterly data)
Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No. shares of common stock outstanding1 | ||||||||||||||||||||||||||
Selected Financial Data (US$) | ||||||||||||||||||||||||||
Operating income (loss) (in thousands) | ||||||||||||||||||||||||||
Operating profit per share2 | ||||||||||||||||||||||||||
Share price1, 3 | ||||||||||||||||||||||||||
Valuation Ratio | ||||||||||||||||||||||||||
P/OP ratio4 | ||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||
P/OP Ratio, Competitors5 | ||||||||||||||||||||||||||
Abbott Laboratories | ||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||
Illumina Inc. | ||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||||
Zoetis Inc. |
Based on: 10-K (filing date: 2021-02-17), 10-Q (filing date: 2020-10-28), 10-Q (filing date: 2020-07-31), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-19), 10-Q (filing date: 2019-10-25), 10-Q (filing date: 2019-08-02), 10-Q (filing date: 2019-05-02), 10-K (filing date: 2019-02-19), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-07-25), 10-Q (filing date: 2018-04-27), 10-K (filing date: 2018-02-20), 10-Q (filing date: 2017-10-27), 10-Q (filing date: 2017-07-28), 10-Q (filing date: 2017-05-01), 10-K (filing date: 2017-02-21), 10-Q (filing date: 2016-10-28), 10-Q (filing date: 2016-07-28), 10-Q (filing date: 2016-04-29).
1 Data adjusted for splits and stock dividends.
2 Q4 2020 Calculation
Operating profit per share
= (Operating income (loss)Q4 2020
+ Operating income (loss)Q3 2020
+ Operating income (loss)Q2 2020
+ Operating income (loss)Q1 2020)
÷ No. shares of common stock outstanding
= ( + + + )
÷ =
3 Closing price as at the filing date of Eli Lilly & Co.’s Quarterly or Annual Report.
4 Q4 2020 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= ÷ =
5 Click competitor name to see calculations.
Valuation ratio | Description | The company |
---|---|---|
P/OP ratio | Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. | Eli Lilly & Co.’s P/OP ratio decreased from Q2 2020 to Q3 2020 but then increased from Q3 2020 to Q4 2020 exceeding Q2 2020 level. |
Price to Sales (P/S)
Eli Lilly & Co., historical P/S calculation (quarterly data)
Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No. shares of common stock outstanding1 | ||||||||||||||||||||||||||
Selected Financial Data (US$) | ||||||||||||||||||||||||||
Revenue (in thousands) | ||||||||||||||||||||||||||
Sales per share2 | ||||||||||||||||||||||||||
Share price1, 3 | ||||||||||||||||||||||||||
Valuation Ratio | ||||||||||||||||||||||||||
P/S ratio4 | ||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||
P/S Ratio, Competitors5 | ||||||||||||||||||||||||||
Abbott Laboratories | ||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||
Illumina Inc. | ||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||||
Zoetis Inc. |
Based on: 10-K (filing date: 2021-02-17), 10-Q (filing date: 2020-10-28), 10-Q (filing date: 2020-07-31), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-19), 10-Q (filing date: 2019-10-25), 10-Q (filing date: 2019-08-02), 10-Q (filing date: 2019-05-02), 10-K (filing date: 2019-02-19), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-07-25), 10-Q (filing date: 2018-04-27), 10-K (filing date: 2018-02-20), 10-Q (filing date: 2017-10-27), 10-Q (filing date: 2017-07-28), 10-Q (filing date: 2017-05-01), 10-K (filing date: 2017-02-21), 10-Q (filing date: 2016-10-28), 10-Q (filing date: 2016-07-28), 10-Q (filing date: 2016-04-29).
1 Data adjusted for splits and stock dividends.
2 Q4 2020 Calculation
Sales per share
= (RevenueQ4 2020
+ RevenueQ3 2020
+ RevenueQ2 2020
+ RevenueQ1 2020)
÷ No. shares of common stock outstanding
= ( + + + )
÷ =
3 Closing price as at the filing date of Eli Lilly & Co.’s Quarterly or Annual Report.
4 Q4 2020 Calculation
P/S ratio = Share price ÷ Sales per share
= ÷ =
5 Click competitor name to see calculations.
Valuation ratio | Description | The company |
---|---|---|
P/S ratio | An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. | Eli Lilly & Co.’s P/S ratio decreased from Q2 2020 to Q3 2020 but then increased from Q3 2020 to Q4 2020 exceeding Q2 2020 level. |
Price to Book Value (P/BV)
Eli Lilly & Co., historical P/BV calculation (quarterly data)
Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No. shares of common stock outstanding1 | ||||||||||||||||||||||||||
Selected Financial Data (US$) | ||||||||||||||||||||||||||
Total Eli Lilly and Company shareholders’ equity (in thousands) | ||||||||||||||||||||||||||
Book value per share (BVPS)2 | ||||||||||||||||||||||||||
Share price1, 3 | ||||||||||||||||||||||||||
Valuation Ratio | ||||||||||||||||||||||||||
P/BV ratio4 | ||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||
P/BV Ratio, Competitors5 | ||||||||||||||||||||||||||
Abbott Laboratories | ||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||
Illumina Inc. | ||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||||
Zoetis Inc. |
Based on: 10-K (filing date: 2021-02-17), 10-Q (filing date: 2020-10-28), 10-Q (filing date: 2020-07-31), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-19), 10-Q (filing date: 2019-10-25), 10-Q (filing date: 2019-08-02), 10-Q (filing date: 2019-05-02), 10-K (filing date: 2019-02-19), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-07-25), 10-Q (filing date: 2018-04-27), 10-K (filing date: 2018-02-20), 10-Q (filing date: 2017-10-27), 10-Q (filing date: 2017-07-28), 10-Q (filing date: 2017-05-01), 10-K (filing date: 2017-02-21), 10-Q (filing date: 2016-10-28), 10-Q (filing date: 2016-07-28), 10-Q (filing date: 2016-04-29).
1 Data adjusted for splits and stock dividends.
2 Q4 2020 Calculation
BVPS = Total Eli Lilly and Company shareholders’ equity ÷ No. shares of common stock outstanding
= ÷ =
3 Closing price as at the filing date of Eli Lilly & Co.’s Quarterly or Annual Report.
4 Q4 2020 Calculation
P/BV ratio = Share price ÷ BVPS
= ÷ =
5 Click competitor name to see calculations.
Valuation ratio | Description | The company |
---|---|---|
P/BV ratio | The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company’s required rate of return and its actual rate of return. | Eli Lilly & Co.’s P/BV ratio decreased from Q2 2020 to Q3 2020 but then increased from Q3 2020 to Q4 2020 not reaching Q2 2020 level. |